Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: CML
Interventions: Imatinib Mesylate, IkT-001Pro; Drug
Lead sponsor: Inhibikase Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Participants
Interventions: AP31969, Carbamazepine, Itraconazole; Drug
Lead sponsor: Acesion Pharma; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: Oxycodone hydrochloride tablet 15 mg, Roxicodone™ tablet 15 mg; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High
Interventions: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab; Biological
Lead sponsor: Simcha IL-18, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Chronic Graft Versus Host Disease, cGVHD
Interventions: Axatilimab, Extracorporeal Photopheresis; Biological · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 12 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: San Francisco, California • Miami, Florida • Chicago, Illinois

Conditions: Influenza, Human
Interventions: over-encapsulated oseltamivir, oseltamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Previously Treated Metastatic Colorectal Cancer
Interventions: SGI-110 Dose Escalation, Regorafenib, TAS-102, SGI-110, Irinotecan; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • New York, New York

Conditions: Food Effects on Pharmacokinetics
Interventions: Milademetan Treatment A, Milademetan Treatment B, Milademetan Treatment C; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Solid Tumor
Interventions: Nemvaleukin alfa, Pembrolizumab; Biological
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Grand Rapids, Michigan • Houston, Texas • West Valley City, Utah + 1 more

Conditions: HIV
Interventions: Taking It to the Pews (Comparison), Taking It to the Pews (Experimental); Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years to 64 Years
Enrollment: 1,540 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin 50 mg, Canagliflozin 100 mg, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Reference, Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) - Test; Drug
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Smoking, Tobacco Use, Tobacco Smoking
Interventions: Product A, Product B, Product C, Product D, Product E, Product F, Product G, Product H; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Rectal Cancer, Colorectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III
Interventions: Prehabilitation Program; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Alcohol Drinking
Interventions: Enhanced Usual Care (pre-operative), Preoperative Virtual Health Coaching, Usual surgical care (post-operative), Postoperative Virtual Health Coaching, On-Track (Post-operative); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 75 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Healthy
Interventions: Telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Alemtuzumab; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: La Jolla, California • La Verne, California • Aurora, Colorado + 4 more

Conditions: Alzheimer Disease
Interventions: Challenge A - low calorie Ensure®, Challenge B - Ensure® plus ketone esters (KE), PET Scan, Cognitive Testing - FCSRT, Story Recall, BVRT, CogState One Card Learning; Dietary Supplement · Procedure · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory
Interventions: Ibrutinib, DA-EPOCH-R, Lenalidomide; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Orange, California + 7 more

Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Testosterone Greater Than 150 ng/dL
Interventions: Daratumumab, FMS Inhibitor JNJ-40346527, Radical Prostatectomy; Biological · Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hemophilia a, Hemophilia B
Interventions: SerpinPC; Drug
Lead sponsor: ApcinteX Ltd; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Aurora, Colorado • Tampa, Florida • Indianapolis, Indiana + 7 more

Conditions: Advanced Solid Tumors, Hematologic Malignancies
Interventions: IXAZOMIB; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Fairway, Kansas • Cleveland, Ohio • Dallas, Texas + 1 more

Conditions: Healthy
Interventions: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Participants
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Search by objective public record fields.

A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg

Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole

Fasting Study of Oxycodone Hydrochloride 15 mg Tablets and Roxicodone™ 15 mg Tablets

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

Church-based HIV Screening: Taking It to the Pews

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

CSD190301: A Study to Assess Elements of Abuse Liability for Two Dissolvable Nicotine Lozenge Tobacco Products

The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial

Alcohol Screening and Preoperative Intervention Research Study - 2

An Open-Label Food Effect Study of Telotristat Etiprate

Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia

The Brain Ketone Body Challenge Imaging Study

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults